Methods of treating pruritic disease with IL-31 monoclonal antibodies
US11542327B2 · kind B2 · utility
0Cited by
82References
28Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2020 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Jan 14, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.